Autism

Yamo Pharmaceuticals Announces Positive Topline Results from Phase 2 Study of L1-79 for the Treatment of the Core Symptoms of AutismYamo Pharmaceuticals Announces Positive Topline Results from Phase 2 Study of L1-79 for the Treatment of the Core Symptoms of Autism

Yamo Pharmaceuticals Announces Positive Topline Results from Phase 2 Study of L1-79 for the Treatment of the Core Symptoms of Autism

Data shows L1-79 offers a statistically significant improvement compared to placebo in socialization, as well as the investigator- and parent-rated…

10 months ago
Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research SymposiumUltragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium

Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium

Presentations will include an encore of the positive interim Phase 1/2 results presented in April at the 76th Annual American…

10 months ago
Beyond Air® to Report First Fiscal Quarter 2025 Financial Results on August 6Beyond Air® to Report First Fiscal Quarter 2025 Financial Results on August 6

Beyond Air® to Report First Fiscal Quarter 2025 Financial Results on August 6

GARDEN CITY, N.Y., July 23, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a…

10 months ago
Spinogenix Announces Enrollment is Open for its Phase 2 Clinical Trial of SPG601 in Fragile X SyndromeSpinogenix Announces Enrollment is Open for its Phase 2 Clinical Trial of SPG601 in Fragile X Syndrome

Spinogenix Announces Enrollment is Open for its Phase 2 Clinical Trial of SPG601 in Fragile X Syndrome

U.S. FDA has granted Orphan Drug Designation to SPG601 for the Treatment of Fragile X Syndrome SPG601 is a novel…

10 months ago
North Shore Pediatric Therapy Expands Locations & Offers Rapid Early Autism Testing Amidst National WaitlistsNorth Shore Pediatric Therapy Expands Locations & Offers Rapid Early Autism Testing Amidst National Waitlists

North Shore Pediatric Therapy Expands Locations & Offers Rapid Early Autism Testing Amidst National Waitlists

Autism testing for kids 4 and under in Arlington Heights, Deerfield, and Naperville fills a much-needed gap for local families.CHICAGO,…

10 months ago
Urban Community Healthcare Center Launches New Program to Address Racial/Economic Disparities in Pediatric Developmental ScreeningsUrban Community Healthcare Center Launches New Program to Address Racial/Economic Disparities in Pediatric Developmental Screenings

Urban Community Healthcare Center Launches New Program to Address Racial/Economic Disparities in Pediatric Developmental Screenings

Dr. Michael Oanea Hired to Pediatric Team at Whittier Street Health, Roxbury, MABOSTON, MA / ACCESSWIRE / July 18, 2024…

10 months ago
SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 millionSciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million

SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million

SciSparc will receive additional payments and execution fees if certain milestones are met TEL AVIV, Israel, July 17, 2024 (GLOBE…

10 months ago
STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of DirectorsSTALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors

STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors

Sarma1 2 Dr. Purnanand Sarma, PhD Press Release Dr. Sarma brings exceptional expertise in all facets of the pharmaceutical and…

10 months ago
SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded CompanySciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company

SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company

According to the agreement, SciSparc’s pharmaceuticals assets are valued at approximately $11.6 million TEL AVIV, Israel, July 08, 2024 (GLOBE…

10 months ago